Advanced search
Publication Cover
Future Oncology Volume 18, 2022 - Issue 17
Submit an article Journal homepage
1,246
Views
0
CrossRef citations to date
0
Altmetric
Short Communication

Phase I/Ib dose-escalation study of avelumab in Chinese patients with advanced solid tumors

Yi-Long Wu1 Guangdong Lung Cancer Institute,Guangdong Provincial People's Hospital,& Guangdong Academy of Medical Sciences,Guangzhou, 510080, ChinaORCID Iconhttps://orcid.org/0000-0002-3611-0258View further author information
ORCID Icon,
Ying Cheng2 Department of Medical Oncology,Jilin Cancer Hospital,Changchun, Jilin, 130012, ChinaView further author information
,
Huajun Chen1 Guangdong Lung Cancer Institute,Guangdong Provincial People's Hospital,& Guangdong Academy of Medical Sciences,Guangzhou, 510080, ChinaView further author information
,
Haiyan Tu1 Guangdong Lung Cancer Institute,Guangdong Provincial People's Hospital,& Guangdong Academy of Medical Sciences,Guangzhou, 510080, ChinaORCID Iconhttps://orcid.org/0000-0001-7125-9878View further author information
ORCID Icon,
Chongrui Xu1 Guangdong Lung Cancer Institute,Guangdong Provincial People's Hospital,& Guangdong Academy of Medical Sciences,Guangzhou, 510080, ChinaORCID Iconhttps://orcid.org/0000-0002-3474-2809View further author information
ORCID Icon,
Zhen Wang1 Guangdong Lung Cancer Institute,Guangdong Provincial People's Hospital,& Guangdong Academy of Medical Sciences,Guangzhou, 510080, ChinaView further author information
,
Ying Liu2 Department of Medical Oncology,Jilin Cancer Hospital,Changchun, Jilin, 130012, ChinaView further author information
,
Ying Xin2 Department of Medical Oncology,Jilin Cancer Hospital,Changchun, Jilin, 130012, ChinaView further author information
,
Haizhou Lou3 Department of Medical Oncology, Sir Run Shaw Hospital,Zhejiang University,Hangzhou, Zhejiang, 310016, ChinaView further author information
,
Wei Wang3 Department of Medical Oncology, Sir Run Shaw Hospital,Zhejiang University,Hangzhou, Zhejiang, 310016, ChinaView further author information
,
Kevin Chin4 EMD Serono Research & Development Institute, Inc.,Billerica,MA 01821, USA, an affiliate of Merck KGaAView further author information
,
Dandan Li5 Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd. Beijing, China, 100022, an affiliate of Merck KGaAView further author information
,
Di Zhao5 Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd. Beijing, China, 100022, an affiliate of Merck KGaAView further author information
,
Yanfei Gao5 Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd. Beijing, China, 100022, an affiliate of Merck KGaAView further author information
,
Wenping Xu5 Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd. Beijing, China, 100022, an affiliate of Merck KGaAView further author information
&
Hongming Pan3 Department of Medical Oncology, Sir Run Shaw Hospital,Zhejiang University,Hangzhou, Zhejiang, 310016, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 2053-2062 | Received 17 Oct 2021, Accepted 09 Mar 2022, Published online: 31 Mar 2022

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.